New combo therapy aims to boost liver cancer treatment
NCT ID NCT07246668
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding a precise type of radiation (carbon ion radiotherapy) to standard immunotherapy drugs (atezolizumab and bevacizumab) can better control advanced liver cancer. About 52 adults with liver cancer that cannot be surgically removed will receive this combination. The goal is to see if the radiation helps shrink tumors and improve survival compared to drugs alone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Yonsei University Health System, Severance Hospital
RECRUITINGSeoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Could a vaccine help fight Hard-to-Treat cancers?
- Could a tailored diet before surgery boost liver cancer recovery?
- Can a new PET tracer light up hidden cancers?
- A new test could reveal how radiation affects the liver
- Can Pre-Surgery immunotherapy prime the immune system to fight head and neck cancer?